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Abstract. There is no standard of care in the UK or Ireland 
for second-line chemotherapy for patients with advanced 
transitional cell carcinoma (TCCU). Vinflunine is approved 
for TCCU patients who have failed a platinum-based regimen, 
and is standard of care in Europe but is not routinely available 
in the UK. Data were collected retrospectively on patients who 
received vinfluine as a second-line treatment. The aims were 
to document the toxicity and efficacy in a real life setting. Data 
were collected on 49 patients from 9 sites across the UK and 
Ireland [median age, 64 (IQR, 57-70) years, 33 males]. All 
patients had advanced metastatic TCCU. Thirteen patients had 
bone or liver metastases, 4 patients had PS 2 and 11 patients 
had HB <10. Median vinflunine administration was 3.5 cycles 
(range 1-18). Most common grade 3-4 toxicities were constipa-
tion (4 patients) and fatigue (3 patients). Partial response rate 
was 29% (14 PR, 11 SD, 19 PD, 4 NE, 1 not available). Median 
OS was 9.1 (6.0, 12.7) months. Results are consistent with real 
life data from Europe. Toxicity is further reduced with prophy-
lactic laxative and oral antibiotics. Vinflunine is an efficient 
and tolerable second line treatment in advanced TCCU.
Introduction
Bladder cancer is a significant cause of morbidity and mortality 
in the UK with ~10,000 new cases diagnosed and 5,000 deaths 
registered each year (1). The most common pathological 
subtype is transitional cell carcinoma (TCCU) (90% of cases) 
(2) with ~50% of all cases being stage II or beyond at the 
time of diagnosis (1). Standard of care for localized, muscle 
invasive TCCU is radical cystectomy, which historically, 
i.e., without modern neoadjuvant combination chemotherapy, 
leads to 5-year overall survival in the approximate range of 
50-60% (3).
A meta-analysis including 11 trials and 3,005 patients 
confirmed the value of preoperative cisplatin based combi-
nation chemotherapy which was shown to reduce the risk of 
relapsing disease and conferring a 5-year absolute overall 
survival advantage of 5% (4). A recent meta-analysis comprising 
945 patients and nine clinical trials similarly demonstrated the 
benefits of postoperative cisplatin based combination chemo-
therapy (5). There is thus significant evidence supporting the 
use of chemotherapy in localized disease. However, not all 
patients are eligible for curative-intent multimodal therapy, 
and about one in five patients present with stage IV disease 
(i.e., locally extending to other organs, to the pelvic or abdom-
inal wall, and/or with evidence of distant metastases) at the 
time of diagnosis (1).
Patients with relapse following primary treatment, or with 
advanced disease at presentation, confer a significant chal-
lenge, and even among those fit for optimal platinum-based 
combination chemotherapy the median overall survival does 
not exceed the range of 12-15 months (6,7). The recommended 
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first line chemotherapy for these patients are cisplatin based 
combinations and either MVAC (methotrexate, vinblastine, 
doxorubicin, and cisplatin) or GC (gemcitabine and cisplatin) 
(6,7) although the GC regimen is often preferred due to a 
milder toxicity profile (7). For patients with acceptable perfor-
mance status and preserved organ functions, and where the 
relapse occurs later than 12 months following neoadjuvant/
adjuvant cisplatin-based combination chemotherapy, change 
of platinum based regimen may be a feasible option (8). In 
selected cases the addition of paclitaxel to gemcitabine and 
cisplatin may be considered (9). For patients unfit for cisplatin 
combinations alternative although potentially less efficient 
combination regimens have been proposed, either with alter-
native platinum agents [oxaliplatin (10) or carboplatin (11)] or 
a platinum-free combination of paclitaxel and gemcitabine 
(12). In patients deemed ineligible for standard cisplatin based 
treatment, combination treatment with split dose cisplatin and 
gemcitabine has reported encouraging results (13).
Following failure of first line chemotherapy, be it early 
relapse following platinum based neoadjuvant/adjuvant 
chemotherapy, or progressive disease during palliative first-
line chemotherapy, treatment options have so far been limited. 
Studies, mostly phase II and retrospective series, have reported 
activity with taxanes and pemetrexed (14). Until recently 
there were no randomized studies to confirm the benefit 
of second line chemotherapy for patients with metastatic 
TCCU. Vinflunine (Javlor®), a microtubule inhibitor of the 
vinca-alkaloid family of anticancer agents (15), is the first 
drug to obtain European Medicine Agency (EMA) approval 
for use in TCCU (2009) due to evidence of efficacy from 
phase II (16,17) and phase III trials (18,19). Considering the 
multiple challenges in the second-line setting, with declining 
performance status due to progressive disease, persistent side 
effects or complications from earlier treatments, and primary 
or acquired chemo resistance after primary chemotherapy, 
the safety profile and efficacy data from the recent vinflunine 
reports are encouraging. In the phase III trial (18,19) median 
overall survival was 6.9 months in the vinflunine plus best 
supportive care compared to 4.3 months in the best supportive 
care only population.
Further empirical studies have confirmed vinflunine to 
be a safe and effective second line approach in Spain [n=66 
(20)], France [n=134 (21)] and Germany [n=77, Hegele (22)] 
with reported overall survival of 7.7-10.4 months. Based 
on the accumulating evidence, the ESMO guidelines now 
suggest vinflunine as the recommended second-line therapy in 
advanced bladder cancer (23).
Vinflunine as a second line therapy is not currently recom-
mended for UK practice, nor is it available to the NHS patients 
through the approved list of drugs on cancer drug fund. It 
has however been made available through the Free of Charge 
Program (FOCP) sponsored by Pierre Fabre. Here we evaluate 
the outcome of patients treated with vinflunine as a second 
line therapy in this program.
Patients and methods
Data were collected retrospectively on patients with advanced 
metastatic TCCU diagnosed between 6th June 1999 and 20th 
June 2013. Data were collected via a pre-defined CRF adopted 
for the study and sent to local investigators for population. 
All patients who received vinflunine as a second line therapy 
following failure of first line therapy were eligible for inclu-
sion.
All patients received vinflunine as a second-line therapy 
through the free of charge program (FOCP) and received at 
least one dose of vinflunine. All patients were included in the 
analysis, irrespective of any dose reductions or toxicities. The 
dose of vinflunine was 320/280/ 250 mg/m2 every 3 weeks 
as per the SPc. The aim was to document the toxicity, radio-
logical RR and OS for patients treated with vinflunine in real 
life setting within the FOCP.
Demographic data were collected on patient gender, age, 
height, weight and performance status as well as the site of the 
disease recurrence and their hemoglobin level at the time that 
the decision to prescribe vinflunine was made. Details on the 
type of first-line therapy were requested as was whether this 
was in the neo-adjuvant or adjuvant setting.
Continuous data are presented as medians (IQR) and 
categorical data are expressed as frequencies of counts. The 
primary outcome measure of interest is overall survival (OS) 
which is measured as the time from intention to treat with vinfl-
unine until death by any cause. Survival estimates obtained via 
method of Kaplan and Meier. Progression-free survival (PFS) 
is measured as the time from first vinflunine administration 
until progression or death by any cause. Objective response 
rate is defined using RECIST criteria (version 1.1) and deter-
mined at each local site. Univariate analyses are carried out to 
assess patient demographics as prognostic factors for overall 
survival using Cox proportional hazards models. Hazard 
ratios (HR) are presented with associated 95% confidence 
intervals (CI). No multivariate analyses were carried out. All 
P-values are considered significant at the 5% level. All analysis 
were carried out using R (version 3.1.2).
Reported toxicities are defined using CTCAE (version 4) 
and are reported based on being either grade 1-2 or 3-4, 
respectively.
Results
Data are provided on 49 patients from nine contributing 
sites throughout the UK and Ireland (CCC 15; Christie 5; 
Cork 6; Glasgow 9; St. George's 1; Royal Free London 2; 
Royal Marsden 6; Northampton 1; Newcastle 4) diagnosed 
with advanced metastatic TCCU between 6th June 1999 and 
20th June 2013. All patients have progression of disease after 
first-line platinum based therapy. Patient demographics are 
provided in Table I. The patient group consists of 67% (33/49) 
males and have a median (IQR) age of 64 (57-70). As per the 
summary of product characteristics (SPC) for vinflunine, 
patients with a 0/1 performance status (ECOG) or a hemo-
globin (Hb) level >10 g/dl were targeted. Thirteen patients 
(27%) had an ECOG performance status of 2 or a hemo-
globin level <10. Sixteen patients (33%) had either bone or 
liver recurrence. Two patients (4%) had chronic constipation 
at presentation and two patients (4%) had coronary artery 
disease.
Information on first-line therapy is available for 48/49 (98%) 
of all participating patients. First line neo-adjuvant chemo-
therapy was given to 60% (27/48) and consisted of gemcitabine/
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cisplatin (74%; 20/27), gemcitabine/carboplatin (22%, 6/27), 
or gemcitabine/cisplatin switched to carboplatin in view of 
worsening renal functions (4%, 1/27). In the metastatic setting 
patients received platinum regimens consisting of either 
gemcitabine/cisplatin (30%, 13/43), gemcitabine/carboplatin 
(37%, 16/43), gemcitabine/cisplatin switched to carboplatin 
(2%, 1/43), or some other combination (30%, 13/43).
Following first-line therapy, patient best response rates were 
complete response 15% (7/48), partial response 48% (23/48), 
stable disease 17% (8/48) and progressive disease 19% (9/48). 
Best response was not available for one patient. The overall 
response rate for first-line therapy was 63% (30/48) and 
98% (43/44) of patients demonstrated disease progression with 
77% (34/44) demonstrating bone, liver, or lung metastases.
Table II gives the details of vinflunine administrations. At 
the point of data collection 248 cycles of vinflunine had been 
administered. The starting dose was 250 mg/m2 (4%, 2/49), 
280 mg/m2 (76%, 37/49) or 320 mg/m2 (20%, 10/49). Three 
patients (6%) had a dose escalation and 10 (21%) had dose 
reduction. The median (IQR) number of cycles given was 3.5 
(2-6.25). Eight patients (17%) had only a single cycle, while 
the maximum number of cycles at the time of analysis was 18.
Toxicity. Toxicities are reported by sites as being either 
grade 1/2 or grade 3/4 hematological or non-hematological. 
Results are given in Table III. Overall 31% (15/49) of patients 
reported at least one grade 3/4 adverse event. The most common 
grade 3/4 toxicities are constipation reported by 8% (4/49) and 
asthenia/fatigue reported by 6% (3/49) of patients.
Overall survival. Patients were followed up for a median of 
9.1 months. At the time of analysis, 41 (84%) patients had 
died. Overall survival estimates obtained via the method of 
Kaplan-Meier (Fig. 1) give a median (95% confidence interval) 
of 9.1 months (6.0-12.7). ECOG performance measures were 
investigated further as a key prognostic indicator of interest 
(Fig. 2). Median survival estimates of 13.1 (6.0, NA) months and 
7.6 (5.98-10.5) months were observed for ECOG performance 
measures of 0 and 1-2, respectively. This was not significant 
statistically [HR (95% CI): 1.62 (0.74, 3.55); P=0.23].
Disease progression. A total of 45 (92%) of patients had disease 
progression at the time of analysis. Median progression-free 
survival estimates (Fig. 2) are 5.1 months (4.3-8.7).
Patient response. Forty-eight patients were evaluable for 
overall response (Table IV). One patient did not provide any 
response data.
Table I. Patient characteristics.
Category Level n=49
Gender Female   16 (33%)
 Male   33 (67%)
Weight, kg Median (IQR)   71 (63-83)
Height, cm Median (IQR) 168 (160-175)
Age, years Median (IQR)   64 (57-70)
Performance 0   12 (26%)
status (n=46) 1   30 (65%)
 2     4   (9%)
Site of disease Bone     8 (17%)
recurrence (n=46) Liver   11 (24%)
 Lung   15 (33%)
 Other visceral     8 (17%)
 Other non-visceral     3 (7%)
 None     1 (2%)
Hemoglobin  <10   11 (28%)
(g/dl) 10-12   20 (50%)
 >12     9 (22%)
Table II. Vinflunine administration.
Category Level 
Starting dose (mg/m2) 250   2 (4%)
 280 37 (75%)
 320 10 (21%)
Escalation (n=47) No 44 (94%)
 Yes   3   (6%)
Reduction (n=47) No 37 (79%)
 Yes 10 (21%)
Cycles Median (IQR) 3.5 (2-6.25)
Table III. Reported hematological and non-hematological 
toxicities.
 Grade --------------------------------------------
Toxicity 1 -2 3-4
Hematological
 Anemia   5 2
 Neutropenia 13 1
 Neutropenic infection   0 2
 Thrombocytopenia   2 0
 Febrile infection   1 0
 Leukopenia   1 1
 Other   0 2 
Non-hematological
 Constipation 9 4
 Asthenia/fatigue 20 3
 Vomiting   8 0
 Abdominal pain   2 0
 Other   0 2
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Sensitivity analyses report the result only on patients who 
meet the SPC (ECOG <2, HB >10). Here 35 patients gave an 
estimated OS of 9.9 months (7.6-16.4) with an estimated PFS 
of 6.0 months (4.8-12.1) and a partial response rate of 30%.
Discussion
The prognosis for patients with advanced metastatic TCCU 
who have progressed after first-line therapy remains dismal, 
and whilst previously published randomised trials and empir-
ical evidence have favoured the use of vinflunine in this patient 
group, the results have not been clear enough to favour its wide 
spread use in the UK. As a consequence, many patients will 
end antitumour therapy or proceed onto palliative care once 
the first-line regimen has failed.
We performed a retrospective observational study in this 
clinical setting to assess the effects of vinflunine in terms of 
both efficacy and toxicity. Data on 49 patients from sites across 
the UK and Ireland were collected and analysed. The dose of 
and number of cycles were consistent with previous studies, 
with a median of 3.5 cycles being similar to the number 
recorded in the phase III trial (18,19). The most common 
starting dose was 280 g/m2 (75%) and the dose was relatively 
well tolerated with only 10 (29%) patients requiring a reduc-
tion. There was no evidence of any correlation between the 
starting dose and dose reduction.
Further to this, the present median overall survival of 
9.1 months (6.0-12.7) is consistent with or even slightly better 
than the 6.9 months of the vinflunine treated arm of the 
Bellmunt phase III study (18,19). Further, the present numbers 
compare favourably with the empirical ‘real life’ results 
obtained from Spain (16) Germany (22) and France (21) which 
all report median survivals between 7.7-10.4 months in similar 
patient populations.
Toxicity rates observed in our study also show little cause 
for concern with 39% (19/49) patients reporting a grade 3+ 
adverse event, the most common being constipation (4 patients) 
and fatigue (3 patients). Toxicity can be further improved with 
the use of prophylactic laxative and oral antibiotics and should 
provide little concern in the prescribing of vinflunine.
Further inspection of study efficacy shows that patients 
with a baseline ECOG PS of 0 display a median OS of 13.1 
(6.0, NA) months, while patients of PS 1-2 have a poorer prog-
nosis of 7.6 (6.0-10.5) months. This is consistent with the data 
of ref. 20 reporting survival estimates of 13.2 and 6.7 months, 
respectively, for the same patient groups and emphasise base-
line PS as a key prognostic predictor although not ruling out 
the potential benefits even in the PS 1-2 population.
This study is limited by the retrospective nature of the 
data collection and the lack of a randomised comparative arm 
against which to compare the efficacy, which ultimately open 
the study results to possible bias. In saying that, however, the 
study analysis includes patients who did not meet the SPC 
for vinflunine as well as patients who only received a single 
dose. Coupled with the high rate of ECOG >0 and the distri-
bution of metastases this suggests a patient population which 
is representative of general clinical practice rather than a 
narrowly selected clinical trial population. Recently there 
has been much interest in the role of immune checkpoint 
inhibitors in urothelial cancer with durable responses have 
been noted with PD1 [e.g., pembrolizumab (24) and PDL1 
atezolizumab (25)]. The results of recently completed trials 
comparing anti-PD1/PDL1 antibodies, with standard of care 
chemotherapy of institution's choice that includes vinflunine 
in the 2nd line setting (NCT 02256436) are awaited with 
interest.
In conclusion, the empirical results obtained from UK and 
Ireland practice reflect what has been observed in randomised 
trials of vinflunine as well as other retrospective studies 
Figure 1. Kaplan-Meier plot of overall survival.
Figure 2. Kaplan-Meier plot for progression-free survival.
Table IV. Overall best response for vinflunine administration.
 Best response




NE   4   (8%)
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throughout the European Union. The accumulating evidence 
puts forward vinflunine single drug therapy as an efficient, 
safe and reasonably tolerable second-line therapy in patients 
with advanced TCCU.
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